Overall survival | |||||||||
---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | |||||||
HR | (95%CI) | p= | HR | (95%CI) | p= | HR | (95%CI) | p= | |
PSA,ng/ml | |||||||||
≤10ng/ml | 1.0 | 1.0 | 1.0 | ||||||
>10ng/ml | 0.54 | (0.15-2.03) | 0.4 | 0.48 | (0.12-1.86) | 0.3 | 0.48 | (0.12-1.87) | 0.3 |
Extra-prostatic extension | |||||||||
Yes | 1.0 | 1.0 | (0.76-17.35) | 1.0 | |||||
No | 3.43 | (0.73-16.12) | 0.1 | 3.63 | 0.1 | 3.48 | (0.73-16.54) | 0.1 | |
Pelvic nodes involved | |||||||||
N0 | 1.0 | 1.0 | 1.0 | ||||||
N+ | 1.71 | (0.50-5.79) | 0.4 | 1.44 | (0.43-4.83) | 0.5 | 1.40 | (0.42-4.72) | 0.6 |
Surgical margins involved | |||||||||
No | 1.0 | 1.0 | 1.0 | ||||||
Yes | 1.37 | (0.45-4.21) | 0.6 | 1.38 | (0.47-4.01) | 0.6 | 1.33 | (0.45-3.92) | 0.6 |
Seminal vesicles involved | |||||||||
No | 1.0 | 1.0 | 1.0 | ||||||
Yes | 1.39 | (0.49-3.94) | 0.5 | 1.08 | (0.37-3.10) | 0.9 | 1.11 | (0.38-3.25) | 0.8 |
Gleason score | |||||||||
<7 | 1.0 | ||||||||
≥7 | 2.13 | (0.55-8.19) | 0.3 | ||||||
Gleason score | |||||||||
≤7 | 1.0 | ||||||||
>7 | 2.80 | (0.93-8.47) | 0.07 | ||||||
Gleason score | |||||||||
<7 | 1.0 | 0.1 | |||||||
=7 | 1.43 | (0.32-6.40) | 0.6 | ||||||
>7 | 3.52 | (0.79-15.61) | 0.1 | ||||||
Epithelial IRS | |||||||||
>2 | 1.0 | 1.0 | 1.0 | ||||||
≤2 | 3.22 | (0.56-18.48) | 0.2 | 3.09 | (0.51-18.63) | 0.2 | 3.19 | (0.52-19.47) | 0.2 |
Stroma IRS | |||||||||
<12 | 1.0 | 1.0 | 1.0 | ||||||
=12 | 5.85 | (1.82-18.77) | 0.003 | 5.76 | (1.84-18.07) | 0.003 | 5.99 | (1.87-19.22) | 0.003 |